# Genomics Shared Resource

> **NIH NIH P30** · ROSWELL PARK CANCER INSTITUTE CORP · 2020 · $275,153

## Abstract

The Genomics Shared Resource (GSR) works closely with CCSG leadership and members to provide a
centralized, efficient approach of supporting genomic endeavors, while facilitating peer-reviewed funding,
publications and recruitment efforts. GSR provides investigators with an efficient path from discovery to
functional based studies. The GSR offers sample-to-data services, with an expert technical staff performing all
aspects of sample preparation, QC, assay design and analysis. The mission of the GSR is to provide state-of-
the-art instrumentation and expertise that enables CCSG members to acquire and analyze genomic data sets
across basic, translational, clinical and population studies. The GSR is positioned not only for discovery-driven
research, but also for diagnostic applications that complement traditional clinical evaluation of cancer samples.
GSR is involved in the research and design of targeted NGS assays that supports the goals of developing
personalized therapies based on the unique genetic makeup of a patient's cancer. GSR has invested in
developing the technologies for liquid biopsy which will provide state-of-the-art support to CCSG members to
study circulating tumor cells and cell free circulating DNA. In the reporting period (2013-2017), the GSR served
a total of 141 Roswell users, of which 112 (95%) were CCSG members. CCSG members continue to use more
large-scale Next Generation Sequencing (NGS) studies to identify novel cancer-associated genes, and
perform the associated downstream validation and functional studies in both liquid and solid tumors. The
Specific Aims of the GSR are: 1) To provide Roswell Park CCSG members access to leading-edge genomics
technologies to aid in developing, testing and substantiating their scientific hypotheses, thereby advancing our
overall knowledge and understanding of cancer; 2) To elicit collaborative integration of all shared resources for
the benefit of basic and clinical investigators to increase publications and grant funding focused around
genomic technologies and discoveries; 3) To synergize the transition of basic and translational science into
clinical understanding and practice using state-of-the-art genomic technologies. Recently acquired
instrumentation include Illumina NextSeq500 (2017) and NovaSeq6000 (2018). These technologies have
increased GSR capacity, allowed greater data output at a fraction of the cost of previous GSR sequencing
technologies, and significant reduction in average project completion time to less than two weeks. The goal of
the GSR is to stay on the forefront of state-of-the-art genomics technology necessary to address the biological
questions of the CCSG investigators. It is anticipated that the NGS demand will increase over the next five
years.

## Key facts

- **NIH application ID:** 9923572
- **Project number:** 5P30CA016056-43
- **Recipient organization:** ROSWELL PARK CANCER INSTITUTE CORP
- **Principal Investigator:** Sean Glenn
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $275,153
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9923572

## Citation

> US National Institutes of Health, RePORTER application 9923572, Genomics Shared Resource (5P30CA016056-43). Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/grant/nih/9923572. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*